Creating innovation in Pharma and Pharmaceutical Production for better health

Reference number
Coordinator Karolinska Institutet - Swedish Medical Nanoscience Center
Funding from Vinnova SEK 299 473
Project duration May 2018 - December 2019
Status Ongoing
Venture Personal mobility between societal sectors
Call 2017-04722-en

Purpose and goal

This project aims to survey and identify specific details on needs and critical problems in quality control processes faced by Pharma Industry and Biopharmaceutical production facilities. Possible approaches and solutions to these problems will be identified that is achievable within the portfolio SMNC and Getinge Life Science. This project will set the stage for the development of each of these solutions by identifying, competition, obstacles, funding sources, project members and designing action plans and work packages.

Expected results and effects

Projects within this application will set the groundwork for collaboration in application-driven research and research innovation through work plans, research proposals and NABC, TRL analyses. This project will likely result in the initiation of least one short tem project generating a technological ‘proof of concept’ and a long term project resulting in a deliverable prototype, for use in Quality Control Processes in today’s Pharma Industry and Biopharmaceutical production facilities.

Planned approach and implementation

This project will be conducted over a 12-month period. Dr Choong, who is employed at the Swedish Medical Nanoscience Center at KI, will be attached at Getinge Life Science, amounting to a 25 % arrangement. Project 1 will commence from May Dec 2018 and Project 2 will commence from Jan April 2019. The project will receive participation from Getinge Life Science in the form of consultants, use of facilities, databases, reports market analysis and other associated expenditures, to match funding received in the application.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.